Gore Excluder TAMBE Introduced in Japan

December 19, 2025—Gore & Associates G.K. in Minato-ku, Tokyo, Japan, announced the first clinical use in Japan of the Gore Excluder thoracoabdominal branch endoprosthesis (TAMBE).

The endovascular device enables treatment of thoracoabdominal aortic aneurysms (TAAAs) and pararenal aneurysms while preserving blood flow to visceral branches. The thoracoabdominal branch stent graft is approved both in the United States and in Japan, noted the company.

The first procedure with the device in Japan was performed in October 2025 by Takao Ohki, MD, Chief and Professor of Vascular Surgery at Jikei University School of Medicine in Tokyo, Japan, supported by Jason T. Lee, MD, Chief and Professor of Vascular Surgery for Stanford Medicine in Stanford, California.

According to Gore, the TAMBE device is intended for patients with all extents of TAAAs or pararenal aneurysms who meet anatomical criteria and for whom surgical repair is difficult. It is an off-the-shelf branch endoprosthesis used in combination with designated stent grafts whose safety and efficacy have been confirmed.

The company further states that TAMBE combines its newly designed aortic component with other components of stent grafts that Gore commercially provides for endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA) or thoracic EVAR (TEVAR), including the Gore Excluder AAA endoprosthesis, Gore Excluder iliac branch endoprosthesis, Gore Viabahn VBX balloon-expandable endoprosthesis, and Gore TAG conformable thoracic stent graft with Active Control system.

The aortic component includes four portals with a precannulation system for visceral branches, facilitating placement of branch components (Gore Viabahn VBX balloon-expandable endoprosthesis) to maintain perfusion to visceral organs. Its multistage deployment system allows for intraoperative repositioning and directional adjustment.

“There had been no approved minimally invasive treatment option in Japan for aneurysms involving visceral branches such as thoracoabdominal and pararenal aneurysms,” commented Dr. Ohki in the company’s press release. “Many patients at high risk for surgery have remained untreated or treated with suboptimal procedures, including debranching TEVAR/EVAR or physician-modified TEVAR/EVAR. TAMBE offers a potential option for patients who previously had limited treatment options.”

Dr. Ohki added, “Gore’s branched stent grafts, such as Gore TAG thoracic branch endoprosthesis and TAMBE, built on decades of technological expertise Gore has, represent a major advancement in providing proven safe and effective treatment to patients with complex aortic disease.”